Management of Subclinical Hypothyroidism

Initial Assessment

For a patient with a TSH level of 5.246, repeat testing in 3-6 weeks is recommended before initiating treatment, as 30-60% of elevated TSH levels normalize on repeat testing 1
Measure both TSH and free T4 to distinguish between subclinical hypothyroidism (normal free T4) and overt hypothyroidism (low free T4) 1, 2
Consider testing for thyroid peroxidase antibodies (TPO), as positive antibodies indicate autoimmune etiology with higher risk of progression to overt hypothyroidism 1, 2

For TSH >10 mIU/L, levothyroxine therapy is recommended regardless of symptoms 1, 2
For TSH between 4.5-10 mIU/L, treatment decisions should be individualized based on symptoms, presence of TPO antibodies, and other risk factors 1
The median TSH level at which levothyroxine therapy is typically initiated has decreased from 8.7 to 7.9 mIU/L in recent years 1
For asymptomatic patients with TSH 4.5-10 mIU/L, observation rather than immediate treatment is often recommended 2, 3

For women planning pregnancy, more aggressive normalization of TSH is warranted due to association with adverse pregnancy outcomes 1
For patients >70 years or with cardiac disease, a more conservative approach is recommended 1
For patients with symptoms of hypothyroidism, a trial of therapy may be beneficial even with TSH between 4.5-10 mIU/L 1

For patients <70 years without cardiac disease: full replacement dose of approximately 1.6 mcg/kg/day 1, 2
For patients >70 years or with cardiac disease: start with lower dose of 25-50 mcg/day and titrate gradually 1, 2

Monitor TSH every 6-8 weeks while titrating hormone replacement 1, 2
Once adequately treated, repeat testing every 6-12 months or if symptoms change 1, 2
Free T4 can help interpret ongoing abnormal TSH levels during therapy 1

Overtreatment risks include development of subclinical hyperthyroidism in 14-21% of treated patients, increasing risk for atrial fibrillation, osteoporosis, and fractures 1, 2
Undertreatment risks include persistent hypothyroid symptoms, adverse effects on cardiovascular function, lipid metabolism, and quality of life 1, 2
Failing to recognize transient hypothyroidism may lead to unnecessary lifelong treatment 1
Adjusting doses too frequently before reaching steady state (should wait 6-8 weeks between adjustments) 1

The evidence supporting treatment for subclinical hypothyroidism with TSH >7 mIU/L is rated as "fair" by expert panels 1, 2
For TSH levels between 4.5-7 mIU/L, evidence for treatment benefits is less consistent 1